Bio-Rad Laboratories, Inc.
BIO
$305.56
-$0.99-0.32%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.20% | 124.08% | -571.33% | -189.38% | -388.81% |
| Total Depreciation and Amortization | 8.36% | 5.95% | 3.53% | 3.91% | 3.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.27% | -103.11% | 267.19% | 113.12% | 118.26% |
| Change in Net Operating Assets | 52.13% | 119.71% | -86.47% | -43.44% | -48.78% |
| Cash from Operations | 19.30% | 54.34% | 48.68% | 21.42% | 10.30% |
| Capital Expenditure | 6.21% | 3.33% | 0.84% | -5.69% | -10.54% |
| Sale of Property, Plant, and Equipment | -73.98% | -80.46% | -74.50% | -74.50% | 29.80% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.62% | 17.03% | -77.91% | -96.95% | 171.83% |
| Cash from Investing | -223.49% | -1,657.09% | -340.14% | -893.29% | 47.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 38.11% | 22.50% | 41.71% | 11.80% | -11.99% |
| Issuance of Common Stock | -19.47% | -8.70% | -8.00% | 3.84% | 6.06% |
| Repurchase of Common Stock | 27.55% | -0.45% | 32.14% | 53.33% | -24.89% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,897.17% | -4,897.17% | -4,897.17% | -- | -1,150.00% |
| Cash from Financing | 20.46% | -10.03% | 26.37% | 48.58% | -26.16% |
| Foreign Exchange rate Adjustments | 9.63% | -343.64% | -5.40% | 2,230.25% | 34.56% |
| Miscellaneous Cash Flow Adjustments | -1,300.00% | -- | -- | -- | -90.70% |
| Net Change in Cash | 69.57% | -308.65% | 391.21% | 383.66% | 23.12% |